Amit Rakhit - 14 Jul 2021 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role: President and CMO
Signature: /s/ Danielle Mann for Amit Rakhit by PoA
Issuer symbol: OVID
Transactions as of: 14 Jul 2021
Net transactions value: -$61,911
Form type: 4
Filing time: 16 Jul 2021, 18:21:39 UTC
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OVID	Common Stock	Options Exercise	$64,292	+34,017	+4.7%	$1.89	760,840	14 Jul 2021	Direct
transaction	OVID	Common Stock	Sale	$126,203	-34,017	-4.5%	$3.71	726,823	14 Jul 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OVID	Stock Option (Right to Buy)	Options Exercise	$0	+34,017	+60%	$0.000000	90,983	14 Jul 2021	Common Stock	34,017	$1.89	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.745, inclusive. The reporting person undertakes to provide to Ovid Therapeutics Inc, any security holder of Ovid Therapeutics Inc, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4
F2	25% of the Stock Options vested and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.745, inclusive. The reporting person undertakes to provide to Ovid Therapeutics Inc, any security holder of Ovid Therapeutics Inc, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4

25% of the Stock Options vested and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.